RELMADA THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted
RELMADA THERAPEUTICS, INC. (RLMD) reported Net Income (Loss) Attributable to Parent, Diluted of -$1.64 million for the 3-month period ending 2016-09-30, per its 10-Q filed 2016-11-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2017-05-15
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2016-09-30 was -$1.64M, a 135.18% decline year-over-year.
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2016-03-31 was -$1.86M.
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2015-12-31 was -$2.46M, a 145.11% decline year-over-year.
- RELMADA THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2015-09-30 was $4.66M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2016-09-30 | -$1.64M 10-Q · filed 2016-11-10 | ||
| 2016-03-31 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-15 | -$4.32M derived: sum of 2 quarters · filed 2017-05-15 | $342.70K 10-Q · filed 2017-05-15 |
| 2015-12-31 | -$2.46M 10-Q · filed 2016-02-05 | $2.20M 10-Q · filed 2017-02-10 | |
| 2015-09-30 | $4.66M 10-Q · filed 2016-11-10 | ||
| 2014-12-31 | $5.46M 10-Q · filed 2016-02-05 | -$24.38M 10-Q · filed 2016-02-05 | |
| 2014-09-30 | -$29.84M 10-Q · filed 2015-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |